

# William C Zamboni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6376610/publications.pdf>

Version: 2024-02-01

92  
papers

5,163  
citations

87843

38  
h-index

88593

70  
g-index

95  
all docs

95  
docs citations

95  
times ranked

8127  
citing authors

#	ARTICLE	IF	CITATIONS
1	Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance. <i>Clinical Cancer Research</i> , 2012, 18, 3229-3241.	3.2	220
2	Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children. <i>Journal of Clinical Oncology</i> , 1999, 17, 1815-1815.	0.8	217
3	Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents. <i>Clinical Cancer Research</i> , 2005, 11, 8230-8234.	3.2	212
4	Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents. <i>Oncologist</i> , 2008, 13, 248-260.	1.9	158
5	Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 329-336.	1.1	151
6	Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 686-693.	1.7	141
7	Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. <i>Clinical Cancer Research</i> , 2012, 18, 5290-5303.	3.2	118
8	Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma Xenografts. <i>Journal of the National Cancer Institute</i> , 1998, 90, 505-511.	3.0	117
9	Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. <i>Nano Letters</i> , 2017, 17, 242-248.	4.5	94
10	Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. <i>Clinical Cancer Research</i> , 2014, 20, 6083-6095.	3.2	89
11	Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts. <i>Clinical Cancer Research</i> , 2007, 13, 7217-7223.	3.2	87
12	Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 43-50.	1.1	87
13	Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e61359.	1.1	77
14	Nanoparticles and the Mononuclear Phagocyte System: Pharmacokinetics and Applications for Inflammatory Diseases. <i>Current Rheumatology Reviews</i> , 2014, 10, 22-34.	0.4	77
15	Factors Affecting the Pharmacology of Antibody-Drug Conjugates. <i>Antibodies</i> , 2018, 7, 10.	1.2	75
16	A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. <i>Science Advances</i> , 2020, 6, eaay9249.	4.7	73
17	Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 599-606.	1.3	69
18	The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. <i>Nanomedicine</i> , 2015, 10, 447-463.	1.7	67

#	ARTICLE	IF	CITATIONS
19	Cancer nanomedicines: closing the translational gap. <i>Lancet, The</i> , 2014, 384, 2175-2176.	6.3	66
20	Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. <i>Journal of Liposome Research</i> , 2012, 22, 177-192.	1.5	65
21	Pharmacokinetic Optimisation of Cancer Chemotherapy. <i>Clinical Pharmacokinetics</i> , 1997, 32, 324-343.	1.6	64
22	Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 454-460.	1.1	62
23	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 920-930.	1.9	62
24	Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 1466-1472.	3.2	61
25	Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice. <i>Clinical Cancer Research</i> , 2013, 19, 4889-4899.	3.2	56
26	Local iontophoretic administration of cytotoxic therapies to solid tumors. <i>Science Translational Medicine</i> , 2015, 7, 273ra14.	5.8	56
27	Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. <i>Journal of Controlled Release</i> , 2019, 311-312, 138-146.	4.8	53
28	Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. <i>ACS Nano</i> , 2016, 10, 861-870.	7.3	51
29	Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 109-117.	1.7	47
30	Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. <i>Journal of Liposome Research</i> , 2011, 21, 158-165.	1.5	46
31	Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. <i>Journal of Controlled Release</i> , 2015, 204, 70-77.	4.8	43
32	Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations. <i>Advanced Drug Delivery Reviews</i> , 2018, 136-137, 82-96.	6.6	43
33	Topoisomerase I interactive drugs in children with cancer. <i>Investigational New Drugs</i> , 1996, 14, 37-47.	1.2	42
34	Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 259-265.	1.1	42
35	Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 269-276.	1.1	42
36	Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts. <i>Clinical Cancer Research</i> , 2012, 18, 2591-2602.	3.2	42

#	ARTICLE	IF	CITATIONS
37	Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 699-705.	1.1	41
38	Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. <i>Oncologist</i> , 2012, 17, 1303-1316.	1.9	37
39	A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents. <i>Clinical Cancer Research</i> , 2013, 19, 3309-3315.	3.2	35
40	Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. <i>Clinical Cancer Research</i> , 2002, 8, 2992-9.	3.2	35
41	Population Pharmacokinetics of Pegylated Liposomal CKD602 (SCKD602) in Patients With Advanced Malignancies. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 180-194.	1.0	34
42	Allometric scaling of pegylated liposomal anticancer drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 653-669.	0.8	32
43	Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 32, 102345.	1.7	32
44	A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 119, 122-129.	1.4	30
45	Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 1996-2009.	2.3	29
46	Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?. <i>Drug Resistance Updates</i> , 2001, 4, 273-288.	6.5	28
47	Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. <i>Journal of Liposome Research</i> , 2011, 21, 70-80.	1.5	28
48	Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 417-426.	1.1	23
49	Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1797-1807.	1.7	22
50	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. <i>Antibodies</i> , 2019, 8, 3.	1.2	22
51	Summary Report of PQRI Workshop on Nanomaterial in Drug Products: Current Experience and Management of Potential Risks. <i>AAPS Journal</i> , 2015, 17, 44-64.	2.2	20
52	Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 565-573.	1.1	20
53	First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. <i>Investigational New Drugs</i> , 2021, 39, 1047-1056.	1.2	20
54	Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2200-2205.	3.3	18

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs. <i>International Journal of Pharmaceutics</i> , 2017, 526, 443-454.	2.6	17
56	Phase I study of DMP 840 in pediatric patients with refractory solid tumors. <i>Investigational New Drugs</i> , 1998, 16, 45-49.	1.2	16
57	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2073-2081.	0.8	16
58	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. <i>International Journal of Nanomedicine</i> , 2015, 10, 1201.	3.3	16
59	Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 471-482.	1.7	16
60	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa065.	0.4	16
61	Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 21, 102076.	1.7	15
62	Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT). <i>Journal of Nanoparticle Research</i> , 2014, 16, 1.	0.8	14
63	Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1419-1433.	1.5	14
64	Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. <i>Nanomedicine</i> , 2017, 12, 2519-2532.	1.7	14
65	Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems. <i>Pharmaceutics</i> , 2021, 13, 114.	2.0	14
66	An Overview of the Pharmacokinetic Disposition of Darbepoetin alfa. <i>Pharmacotherapy</i> , 2002, 22, 133S-140S.	1.2	13
67	Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 2007-2017.	1.7	13
68	Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective. <i>Antibodies</i> , 2021, 10, 30.	1.2	13
69	Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents. <i>Nanomedicine</i> , 2017, 12, 2021-2042.	1.7	12
70	Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1255-1262.	1.1	11
71	Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. <i>Gynecologic Oncology</i> , 2013, 131, 683-688.	0.6	11
72	Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts. <i>Clinical Cancer Research</i> , 2005, 11, 4867-4874.	3.2	10

#	ARTICLE	IF	CITATIONS
73	Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 61-70.	1.1	10
74	Challenges in preclinical to clinical translation for anticancer carrier-mediated agents. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2016, 8, 642-653.	3.3	9
75	Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. <i>International Journal of Nanomedicine</i> , 2012, 7, 5555.	3.3	8
76	Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study. <i>PLoS ONE</i> , 2017, 12, e0186018.	1.1	8
77	Phase I study of docetaxel and topotecan in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 442-448.	1.1	6
78	Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice. <i>Investigational New Drugs</i> , 2008, 26, 399-406.	1.2	6
79	Bidirectional Interaction Between Nanoparticles and Cells of the Mononuclear Phagocytic System. <i>Frontiers in Nanobiomedical Research</i> , 2013, , 385-416.	0.1	6
80	Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents. <i>Methods in Molecular Biology</i> , 2018, 1831, 201-228.	0.4	6
81	Steroid Eluting Esophageal-Targeted Drug Delivery Devices for Treatment of Eosinophilic Esophagitis. <i>Polymers</i> , 2021, 13, 557.	2.0	6
82	A mucoadhesive biodissolvable thin film for localized and rapid delivery of lidocaine for the treatment of vestibulodynia. <i>International Journal of Pharmaceutics</i> , 2021, , 121288.	2.6	6
83	Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2015, 138, 548-553.	0.6	5
84	Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. , 2021, 4, 382-413.		5
85	Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110537.	1.4	5
86	Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 147-152.	1.2	4
87	Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optosomal topotecan (TLI) in rats. <i>Cancer Research</i> , 2010, 70, 3700-3700.	0.4	4
88	Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains. <i>Genes, Brain and Behavior</i> , 2021, 20, e12666.	1.1	3
89	Bidirectional Interaction between Nanoparticles and Carrier-Mediated Agents and Cells of the Mononuclear Phagocytic System. <i>Frontiers in Nanobiomedical Research</i> , 2016, , 1-41.	0.1	1
90	It takes a village to raise awareness of and to address surface contamination of hazardous drugs. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 558-560.	0.5	1

#	ARTICLE	IF	CITATIONS
91	SCIDOT-03. HYPERLOADED POLY(2-OXAZOLINE) MICELLES AS PERSONALIZED DRUG CARRIERS FOR BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi272-vi273.	0.6	1
92	Abstract 754: The effect of CC chemokine ligand-2 (CCL2/MCP-1) and CC chemokine ligand-5 (CCL5/RANTES) on the pharmacokinetics (PK) and the pharmacodynamics (PD) of pegylated liposomal CKD602 (S-CKD602) in patients with advanced solid tumors. , 2012, , .		1